Detail akcie Immuneering Rg-A online

Business Summary: Immuneering Corporation is a clinical-stage oncology company. The Company is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Company’s lead product candidate, IMM-1-104, is in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve universal-RAS activity through deep cyclic inhibition of the mitogen-activated protein kinase (MAPK) pathway. The Company’s second product candidate, IMM-6-415, is an oral, twice-daily deep cyclic inhibitor of mitogen-activated protein kinase kinase (MEK) in a Phase I/IIa trial in patients with advanced solid tumors harboring RAS or RAF mutations. Its pipeline also includes RAS modulators and other small molecule drug discovery programs. The Company’s platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Immuneering Corp revenues was not reported. Net loss increased 4% to $29.5M. Higher net loss reflects Interest Income decrease of 53% to $763K (income), Research and development - Balancing increase of 4% to $14.5M (expense), Other income (expense) decrease from $221K (income) to $0K. Basic Earnings per Share excluding Extraordinary Items increased from -$0.96 to -$0.82.